COMPARISON OF SITA STANDARD 24-2 WITH SITA FASTER 24-2C PROGRAM ON HUMPHREY FIELD ANALYZER IN ASSESSING VISUAL FIELD DEFECTS OF GLAUCOMA PATIENTS Oral Presentation - Observational Study - Resident
Article Sidebar
-
glaucoma, visual field, Humphrey,, SITA strategy
Abstract
Introduction & Objectives
Introduction: Periodical perimetry examination to detect and determine the rate of glaucoma
progression continues to be a challenging task, because it depends on many factors. Besides, there
is now a paradigm shift which central visual field defects occur earlier. SITA Standard (SS) 24-2 is
the clinical standard for glaucoma examination, but there were studies reporting on the prevalence
of central visual field defects not detected. SITA Faster (SFR) 24-2C was developed to address
current shortcomings, but the performance has yet to be formally and independently assessed.
Objectives: To compare the global indices (Mean Deviation, Pattern Standard Deviation, Visual Field
Index) and test duration between SS 24-2 and SFR 24-2C program.
Methods
This is an analytical observational study with a cross-sectional design. Subjects aged >18 years who
diagnosed with glaucoma and whose visual fields unaffected by other condition besides glaucoma
were included. All subjects underwent testing of both programs.
Results
This study was conducted in 94 eyes of 66 patients. Comparison of global indices and test duration
between the two programs was carried out by the Wilcoxon test. The mean results of MD and PSD
global indices were not significantly different, however there was a difference in the mean VFI of
1.5% between the two programs. The test duration of SFR 24-2C was 55.03% faster.
Conclusion
There was no significant difference in the MD and PSD global indices, but there was a significant
difference in the VFI, as well as the test duration between the two programs.
Full text article
References
Kyei S, Obeng PA, Kwarteng MA, et al. Epidemiology and Clinical Presentation of Glaucoma in a Referral Facility in Ghana: Any lessons for Public Health Intervention?. PLoS ONE 16(1): e0245486. 2021.
Rapuano CJ, Stout JT, McCannel CA. Introduction to Glaucoma: Terminology, Epidemiology, and Genetics. In: Basic Science and Clinical Course Section 10: Glaucoma. San Fransisco: American Academy of Ophthalmology; 2020. Pages 313.
Tham YC, Li X, Wong T-Y, et al. Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040 A Systemic Review and Meta-Analysis. PubMed. June 2014. Ophthalmology 121(11).
The International Agency for the Prevention of Blindness. Global Vision Database Maps [Internet]. IAPB Vision Atlas. 2017.
Allison K, Patel D, Alabi O. Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future. Cureus. 2020 Nov; 12(11): e11686.
Hu R, Racette L, Chen KS, et al. Functional Assessment of Glaucoma: Uncovering Progression. Elsevier; 2020, pages 639-661.
Abu SL, Marin-Franch I, Racette Lyne. A Framework for Assessing Glaucoma Progression Using Structural and Functional Indices Jointly. PLoS ONE 15(7): e0235255. 2020.
Tatham AJ, Murray IC, McTrusty AD, et al. A Case Control Study Examining the Feasibility of Using Eye Tracking Perimetry to Differentiate Patients with Glaucoma from Healthy Controls. Nature Research. (2021)11:839.
Wu Zhichao, Medeiros FA. Recent Developments in Visual Field Testing for Glaucoma. Curr Opin Ophthalmol 2018, 29:141-146.
Liebmann JM. High-tech Mythbusting: Glaucoma and the Macula. Review of Opthalmology; 2017.
Traynis I, De Moraes CG, Raza AS, et al. The Prevalence and Nature of Early Glaucomatous Defects in the Central 10o of the Visual Field. JAMA Ophthalmol. 2014 Mar; 132(3): 291-297.
Phu J, Kalloniatis. Ability of 24-2C and 24-2 Grid to Identify Central Visual Field Defects and Structure-Function Concordance in Glaucoma and Suspects. Am J Ophthalmol 2020;219:317-331.
Heijl A, Patella VM, Bengtsson B. Excellent Perimetry. 5th Edition. Dublin, CA : Carl Zeiss Meditec Inc.; 2021. Pages 13-42, 225-30.
Epshtein D. ZEISS Humphrey Field Analyzer: Today and Tomorrow. Carl Zeiss Meditec, Inc., 2019.
Belete BK, Assefa NL, Assem AS, et al. Determinants for Late Presentation of Glaucoma Among Adult Glaucomatous Patients in University of Gondar Comprehensive Specialized Hospital. Case Control Study. PLoS ONE 17(4): e0267582.
Ezinne NE, Ojukwu CS, Ekemiri KK, et al. Prevalence and Clinical Profile of Glaucoma Patients in Rural Nigeria – A Hospital Based Study. PLoS ONE 16(12): e0260965.
Vajaranant TS, Nayak S, Wilensky JT, et al. Gender and Glaucoma: What We Know and What We Need to Know. Curr Opin Ophthalmol. 2010 Mar; 21(2): 91–99.
Mahabadi N, Foris LA, Tripathy K. Open Angle Glaucoma. StatPearls Publishing LLC; 2022.
Gardiner SK, Demirel S. Detecting Change Using Standard Global Perimetric Indices in Glaucoma. Am J Ophthalmol. 2017 Apr; 176: 148-156.
Rao HL, Senthil S, Choudhari NS, et al. Behavior of Visual Field Index in Advanced Glaucoma. Investigative Ophthalmology & Visual Science January 2013, Vol.54, 307312.
Bengtsson B, Heijl A. A Visual Field Index for Calculation of Glaucoma Rate of Progression. Am J Ophthalmol 2008;145(2):343-353.
Lee GC, Yu S, Callan T, et al. Diagnostic Efficacy of 24-2 and 24-2C SITA Faster Global Summary Indices. Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2455.
Cho JW, Sung KR, Yun SC, et al. Progression Detection in Different Stages of Glaucoma: Mean Deviation versus Visual Field Index. Jpn J Ophthalmol (2012) 56: 128-133.
Heijl A, Patella VM, Bengtsson B. Effective Perimetry. 4th Edition. Dublin, CA : Carl Zeiss Meditec Inc.; 2012. Pages 1-10, 21-60.
Heijl A, Patella VM, Chong LX, et al. A New SITA Perimetric Threshold Testing Algorithm: Construction and a Multicenter Clinical Study. American Journal of Ophthalmology. Volume 198, February 2019, Pages 154-165.
Yu S, Lee GC, Callan T, et al. Comparison of SITA Faster 24-2C Test Times to Legacy SITA Tests. Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2454.
Authors
Copyright (c) 2023 Nuzul Rianti, Karmelita Satari, Elsa Gustianty, Andika Prahasta, R. Maula Rifada, Sonie Umbara
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.